Skip to main content
Article thumbnail
Location of Repository

Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups

By Marysia Hengeveld, Stefan Suciu, Matthias Karrasch, Giorgina Specchia, Jean-Pierre Marie, Petra Muus, Maria C. Petti, Bruno Rotoli, Sergio Amadori, Guiseppe Fioritoni, Pietro Leoni, Enrica Morra, Joseph Thaler, Luigi Resegotti, Paola Fazi, Marco Vignetti, Franco Mandelli, Robert Zittoun and Theo de Witte

Abstract

The most effective post-remission treatment to maintain complete remission (CR) in adults aged between 46 and 60 years with acute myeloid leukaemia (AML) is uncertain. Previously untreated patients with AML in CR after induction chemotherapy with daunorubicin and cytarabine were randomized between two intensive courses of consolidation therapy containing high-dose cytarabine, combined with amsacrine or daunorubicin and a standard consolidation and maintenance therapy containing standard dose cytarabine and daunorubicin. One hundred fifty-eight CR patients were assigned to the intensive group and 157 patients to the standard group. After a median follow-up of 7.5 years, the 4-year survival rate was 32 % in the intensive group versus 34 % in the standard group (P = 0.29). In the intensive group, the 4-year relapse incidence was lower than in the standard group: 55 and 75 %, respectively (P = 0.0003), whereas treatment-related mortality incidence was higher: 22 versus 3 % (P < 0.0001). Two intensive consolidation courses containing high-dose cytarabine as post-remission treatment in patients with AML aged between 46 and 60 years old did not translate in better long-term outcome despite a 20 % lower relapse incidence. Better supportive care and prevention of treatment-related complications may improve the overall survival after intensified post-remission therapy in this age group

Topics: Original Article
Publisher: Springer-Verlag
OAI identifier: oai:pubmedcentral.nih.gov:3345117
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (1996). A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
    2. (2005). A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine.
    3. (2006). Acute myeloid leukaemia.
    4. (2007). Acute myeloid leukemia and the position of autologous stem cell transplantation.
    5. (1989). Alternating v repeated post-remission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group.
    6. (2009). Anthracycline dose intensification in acute myeloid leukemia.
    7. (2001). Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.
    8. Craddock C et al (2006) Guidelines on the management of acute myeloid leukaemia in adults.
    9. Daenen SM et al (2007) Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
    10. (2009). Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia:
    11. (2005). Drug therapy for acute myeloid leukemia.
    12. Ferrant A et al (2009) High-dose daunorubicin in older patients with acute myeloid leukemia.
    13. (1998). Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    14. (1985). Gralnick HR et al
    15. (1996). Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
    16. (1985). High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot study.
    17. (2000). How I treat older patients with AML.
    18. (2011). Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.
    19. (1994). Intensive postremission chemotherapy in adults with acute myeloid leukemia.
    20. (1992). Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia.
    21. (2003). Mixed discrete and continuous Cox regression model.
    22. Paciucci PA,Schulman PP et al (2001) Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.
    23. (2002). Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.
    24. (1997). Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK).
    25. (2009). Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a ‘donor’ versus ‘no donor’ comparison.
    26. (1996). Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phaseII study (no. 06901) of the EORTC Leukemia Cooperative Group.
    27. (2002). The difficult problem of acute myeloid leukemia in the older adult.
    28. (1992). Varying intensity of postremission therapy in acute myeloid leukemia.
    29. Verdonck LF et al (2010) Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study.
    30. (1999). Wormann B et al

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.